Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression

Pharmacogenetics

Volumn 9, Issue 3, 1999, Pages 357-366

  Schulz Utermoehl, Timothy ^a   Bennett, Andrew J ^b   Ellis, S Wynne ^b   Tucker, Geoffrey T ^b   Boobis, Alan R ^a   Edwards, Robert J ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

CYP2D; Cytochrome P450; Dark Agouti rat; Debrisoquine

Indexed keywords

ANTIBODY; CYTOCHROME P450; DEBRISOQUINE; DEBRISOQUINE 4 HYDROXYLASE; LIVER ENZYME; METOPROLOL; RECOMBINANT ENZYME; SYNTHETIC PEPTIDE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG OXIDATION; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; IMMUNOBLOTTING; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SEX DIFFERENCE; STRAIN DIFFERENCE;

AGOUTI; ANIMALIA; CINCHONA PUBESCENS; ORYCTOLAGUS CUNICULUS; RATTUS NORVEGICUS; RODENTIA;

EID: 0032792189     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199906000-00011     Document Type: Article

References (43)

1. Adams DA, Edwards RJ, Davies DS, Boobis AR. Specific inhibition of human CYP1A2 using a targeted antibody. Biochem Pharmacol 1997; 54:189-197.
2. Al Dabbagh SG, Idle JR, Smith RL. Animal modelling of human polymorphic drug oxidation - the metabolism of debrisoquine and phenacetin in rat inbred strains. J Pharm Pharmacol 1981; 33:161-164.
3. Ball JM, Henry NL, Montelaro RC, Newman MJ. A versatile synthetic peptide-based ELISA for identifying antibody epitopes. J Immunol Methods 1994; 171:37-44.
4. Boobis AR, Brodie MJ, Kahn GC, Fletcher DR, Saunders JH, Davies DS. Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens. Br J Clin Pharmacol 1980; 9:11-19.
5. Bouchardy C, Benhamou S, Dayer P. The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res 1996; 56:251-253.
6. Cribb A, Nuss C, Wang R. Antipeptide antibodies against overlapping sequences differentially inhibit human CYP2D6. Drug Metab Dispos 1995; 23:671-675.
7. Daly AK, Cholerton S, Gregory W, Idle JR. Metabolic polymorphisms. Pharmacol Ther 1993; 57:129-160.
8. Debri K, Boobis AR, Davies DS, Edwards RJ. Distribution and induction of CYP3A1 and CYP3A2 in rat liver and extrahepatic tissues. Biochem Pharmacol 1995; 50:2047-2056.
9. Edwards RJ, Singleton AM, Sesardic D, Boobis AR, Davies DS. Antibodies to a synthetic peptide that reacts specifically with a common surface region on two hydrocarbon-inducible isoenzymes of cytochrome P-450 in the rat. Biochem Pharmacol 1988; 37:3735-3741.
10. Edwards RJ, Murray BP, Boobis AR. Antipeptide antibodies in studies of cytochromes P4501A. Methods Enzymol 1991; 206:220-233.
11. Edwards RJ, Singleton AM, Murray BP, Davies DS, Boobis AR. Short synthetic peptides exploited for reliable and specific targeting of antibodies to the C-termini of cytochrome P450 enzymes. Biochem Pharmacol 1995; 49:39-47.
12. Edwards RJ, Adams DA, Watts PS, Davies DS, Boobis AR. Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans. Biochem Pharmacol 1998; 56:377-387.
13. Eichelbaum M. Polymorphic drug oxidation in humans. Fed Proc 1984; 43:2298-2302.
14. Ellis SW, Rowland K, Ackland MJ, Rekka E, Simula AP, Lennard MS, et al. Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio-and enantio-selective metabolism of metoprolol. Biochem J 1996; 316:647-654.
15. Gonzalez FJ, Matsunaga T, Nagata K, Meyer UA, Nebert DW, Pastewka J, et al. Debrisoquine 4-hydroxylase: characterization of a new P450 gene subfamily, regulation, chromosomal mapping, and molecular analysis of the DA rat polymorphism. DNA 1987; 6:149-161.
16. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988; 331:442-446.
17. Gonzalez FJ. The CYP2D subfamily. In: Ioannides C, ed. Cytochromes P450: metabolic and toxicological aspects. Boca Raton: CRC Press, 1996; pp. 183-210.
18. Guengerich FP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 1991; 4:391-407.
19. Guengerich FP. Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity. Toxicol Lett 1994; 70:133-138.
20. C-M/F encode for members of P450IID subfamily, increasing the number of members within the subfamily. Biochem Biophys Res Commun 1988; 156:681-688.
21. Kahn GC, Boobis AR, Murray S, Brodie MJ, Davies DS. Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver. Br J Clin Pharmacol 1982; 13:637-645.
22. Kahn GC, Rubenfield M, Davies DS, Murray S, Boobis AR. Sex and strain differences in hepatic debrisoquine 4-hydroxylase activity of the rat. Drug Metab Dispos 1985; 13:510-516.
23. Kawashima H, Strobel HW. cDNA cloning of a novel rat brain cytochrome P450 belonging to the CYP2D subfamily. Biochem Biophys Res Commun 1995; 209:535-540.
24. Kawashima H, Sequiera DJ, Nelson DR, Strobel HW. Genomic cloning and protein expression of a novel rat brain cytochrome P-450 CYP2D18 catalysing imipramine N-demethylation. J Biol Chem 1996; 271:28176-28180.
25. Kobayashi S, Murray S, Watson D, Sesardic D, Davies DS, Boobis AR. The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. Biochem Pharmacol 1989; 38:2795-2799.
26. Lightfoot T, Ellis SW, Mahling J, Ackland MJ, Blaney EF, Byloo GJ, et al. Regioselective hydroxylation of debrisoquine by cytochrome P450 2D6 - rationalization by active site modelling and mechanisms of oxidation. Drug Metab Dispos (submitted).
27. Larrey D, Distlerath LM, Dannan GA, Wilkinson GR, Guengerich FP. Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism. Biochemistry 1984; 23:2787-2795.
28. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193:265-275.
29. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2:584-586.
30. Matsunaga E, Zanger UM, Hardwick JP, Gelboin HV, Meyer UA, Gonzalez FJ. The CYP2D gene subfamily: analysis of the molecular basis of the debrisoquine 4-hydroxylase deficiency in DA rats. Biochemistry 1989; 28:7349-7355.
31. Matsunaga E, Gonzalez FJ. Specific cytosine demethylations within the first exons of the rat CYP2D3 and CYP2D5 genes are associated with activation of hepatic gene expression during development. DNA Cell Biol 1990; 9:443-452.
32. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6:1-42.
33. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. Evidence for its hemoprotein nature. J Biol Chem 1964; 239:2370-2378.
34. Otton SV, Crewe HK, Lennard MS, Tucker GT, Woods HF. Use of quinidine inhibition to define the role of the sparteine/ debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther 1988; 247:242-247.
35. Rich KJ, Boobis AR. Expression and inducibility of P450 enzymes during liver ontogeny. Microsc Res Tech 1997; 39:424-435.
36. Robertson GR, Farrell GC, Liddle C. Sexually dimorphic expression of rat CYP3A9 and CYP3A18 genes is regulated by growth hormone. Biochem Biophys Res Comm 1998; 242:57-60.
37. Ryan DE, Iida S, Wood AW, Thomas PE, Lieber CS, Levin W. Characterisation of three highly purified cytochromes P-450 from hepatic microsomes of adult male rats. J Biol Chem 1984; 259:1239-1250.
38. Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, et al. The demethylenation of methylenedioxymethamphetamine ('ecstasy') by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 1994; 47:1151-1156.
39. Wan J, Imaoka S, Chow T, Hiroi T, Yabusaki Y, Funae Y. Expression of four rat CYP2D isoforms in Saccharomyces cerevisiae and their catalytic specificity. Arch Biochem Biophys 1997; 348:383-390.
40. Wang RW, Lu AYH. Inhibitory anti-peptide antibody against human CYP3A4. Drug Metab Dispos 1997; 25:762-767.
41. Warwick AP, Redman CW, Jones PW, Fryer AA, Gilford J, Alldersea J, Strange RC. Progression of cervical intraepithelial neoplasia to cervical cancer: interactions of cytochrome P450 CYP2D6 EM and glutathione S-transferase GSTM1 null genotypes and cigarette smoking. Br J Cancer 1994; 70:704-708.
42. Yamamoto Y, Nakamura A, Tasaki T, Umeda S, Sugimoto C, Imaoka S, et al. Impaired expression in DA rats of catalytically active BTL, immunochemically distinguishable from P4502D1: immunological evidence with specific anti-peptide antibodies. Biomed Res 1996; 17:331-337.
43. Yamamoto Y, Tasaki T, Nakamura A, Isawa H, Kazusaka A, Gonzalez FJ, Fujita S. Molecular basis of the Dark Agouti rat drug oxidation polymorphism: importance of CYP2D1 and CYP2D2. Pharmacogenetics 1998; 8:73-82.